<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35766728</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1726-4642</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Season>Jan-Mar</Season></PubDate></JournalIssue><Title>Revista peruana de medicina experimental y salud publica</Title><ISOAbbreviation>Rev Peru Med Exp Salud Publica</ISOAbbreviation></Journal><ArticleTitle>Concurrence between Guillain-Barr&#xe9; syndrome and immune thrombocytopenic purpura possibly induced by long COVID-19.</ArticleTitle><Pagination><StartPage>111</StartPage><EndPage>114</EndPage><MedlinePgn>111-114</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.17843/rpmesp.2022.391.10687</ELocationID><Abstract><AbstractText>During acute SARS-CoV-2 infection, there is persistent deregulation of the immune system that can last up to 8 months after the acute condition is controlled. This, added to other factors, is possibly associated with an increased risk of the appearance and concurrence of autoimmune diseases. The simultaneous occurrence of GBS and ITP has been rarely reported in the literature, and GBS is rarely associated with another autoimmune disease. We present the case of a man who, one month after his recovery from acute moderate COVID-19, presented concurrent GBS and ITP with an adequate response to treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pichardo-Rodr&#xed;guez</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-3316-4557</Identifier><AffiliationInfo><Affiliation>Instituto de Investigaciones en Ciencias Biom&#xe9;dicas (INICIB), Universidad Ricardo Palma, Lima, Per&#xfa;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bracamonte-Hern&#xe1;ndez</LastName><ForeName>Juan-Jes&#xfa;s</ForeName><Initials>JJ</Initials><Identifier Source="ORCID">0000-0002-6448-6404</Identifier><AffiliationInfo><Affiliation>Instituto de Investigaciones en Ciencias Biom&#xe9;dicas (INICIB), Universidad Ricardo Palma, Lima, Per&#xfa;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ram&#xed;rez-Meyhuay</LastName><ForeName>Diana-Cristina</ForeName><Initials>DC</Initials><Identifier Source="ORCID">0000-0003-4683-6711</Identifier><AffiliationInfo><Affiliation>Instituto de Investigaciones en Ciencias Biom&#xe9;dicas (INICIB), Universidad Ricardo Palma, Lima, Per&#xfa;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arquinigo-Lavado</LastName><ForeName>Ingrid-Roxani</ForeName><Initials>IR</Initials><Identifier Source="ORCID">0000-0002-6546-5437</Identifier><AffiliationInfo><Affiliation>Instituto de Investigaciones en Ciencias Biom&#xe9;dicas (INICIB), Universidad Ricardo Palma, Lima, Per&#xfa;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pe&#xf1;a-Oscuvilca</LastName><ForeName>Willy</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-6301-0674</Identifier><AffiliationInfo><Affiliation>Instituto de Investigaciones en Ciencias Biom&#xe9;dicas (INICIB), Universidad Ricardo Palma, Lima, Per&#xfa;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saavedra-Velasco</LastName><ForeName>Marcos</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2977-1020</Identifier><AffiliationInfo><Affiliation>Instituto de Investigaciones en Ciencias Biom&#xe9;dicas (INICIB), Universidad Ricardo Palma, Lima, Per&#xfa;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz-Franco</LastName><ForeName>Oscar</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-7178-9673</Identifier><AffiliationInfo><Affiliation>Facultad de Medicina, Universidad Nacional Mayor de San Marcos, Lima, Per&#xfa;.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><VernacularTitle>Concurrencia entre el s&#xed;ndrome de Guillain-Barr&#xe9; y p&#xfa;rpura trombocitop&#xe9;nica inmune posiblemente inducidos por COVID-19 prolongado.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Peru</Country><MedlineTA>Rev Peru Med Exp Salud Publica</MedlineTA><NlmUniqueID>101227566</NlmUniqueID><ISSNLinking>1726-4634</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020275" MajorTopicYN="Y">Guillain-Barre Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016553" MajorTopicYN="Y">Purpura, Thrombocytopenic, Idiopathic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText>Durante la infecci&#xf3;n aguda por el SARVS-CoV-2 se produce una desregulaci&#xf3;n del sistema inmune que puede durar hasta ocho meses despu&#xe9;s de controlado el cuadro agudo. Esto, sumado a otros factores, posiblemente este asociado con un aumento del riesgo de aparici&#xf3;n y concurrencia de enfermedades autoinmunes. La aparici&#xf3;n simultanea del s&#xed;ndrome de Guillain-Barr&#xe9; (SGB) y p&#xfa;rpura trombocitop&#xe9;nica (PTI) se ha reportado poco en la literatura, y el SGB raramente se asocia con otra enfermedad autoinmune. Presentamos el caso de un var&#xf3;n que luego de un mes de tener un cuadro agudo de COVID-19 moderado, present&#xf3; concurrentemente SGB y PTI con respuesta adecuada al tratamiento.</AbstractText></OtherAbstract><OtherAbstract Type="Publisher" Language="spa"><AbstractText>Durante la infecci&#xf3;n aguda por el SARVS-CoV-2 se produce una desregulaci&#xf3;n del sistema inmune que puede durar hasta ocho meses despu&#xe9;s de controlado el cuadro agudo. Esto, sumado a otros factores, posiblemente este asociado con un aumento del riesgo de aparici&#xf3;n y concurrencia de enfermedades autoinmunes. La aparici&#xf3;n simultanea del s&#xed;ndrome de Guillain-Barr&#xe9; (SGB) y p&#xfa;rpura trombocitop&#xe9;nica (PTI) se ha reportado poco en la literatura, y el SGB raramente se asocia con otra enfermedad autoinmune. Presentamos el caso de un var&#xf3;n que luego de un mes de tener un cuadro agudo de COVID-19 moderado, present&#xf3; concurrentemente SGB y PTI con respuesta adecuada al tratamiento.</AbstractText></OtherAbstract><CoiStatement><b>Conflicts of interest:</b> No conflicts of interest are declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>29</Day><Hour>9</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35766728</ArticleId><ArticleId IdType="pmc">PMC11397667</ArticleId><ArticleId IdType="doi">10.17843/rpmesp.2022.391.10687</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier CML, Patel SK, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022:1&#x2013;7. doi: 10.1038/s41590-021-01113-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortona E, Malorni W. Long COVID to investigate immunological mechanisms and sex/gender related aspects as fundamental steps for a tailored therapy. Eur Respir J. 2022;59(2):2102245&#x2013;2102245. doi: 10.1183/13993003.02245-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.02245-2021</ArticleId><ArticleId IdType="pmc">PMC8462012</ArticleId><ArticleId IdType="pubmed">34531277</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikh AB, Chourasia PK, Javed N, Chourasia MK, Suriya SS, Upadhyay S. Association of Guillain-Barre syndrome with COVID-19 infec&#xac;tion An updated systematic review. J Neuroimmunol. 2021;355:577577&#x2013;577577. doi: 10.1016/j.jneuroim.2021.577577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2021.577577</ArticleId><ArticleId IdType="pmc">PMC8053360</ArticleId><ArticleId IdType="pubmed">33895700</ArticleId></ArticleIdList></Reference><Reference><Citation>Samudralwar RD. Commentary The spectrum of neurological manifestations related to COVID-19 and vaccinations. J Neuroimmunol. 2021;358:577660&#x2013;577660. doi: 10.1016/j.jneuroim.2021.577660.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2021.577660</ArticleId><ArticleId IdType="pmc">PMC8270743</ArticleId><ArticleId IdType="pubmed">34274719</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharjee S, Banerjee M. Immune Thrombocytopenia Secondary to COVID-19: a Systematic Review. SN Compr Clin Med. 2020:1&#x2013;11. doi: 10.1007/s42399-020-00521-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s42399-020-00521-8</ArticleId><ArticleId IdType="pmc">PMC7501509</ArticleId><ArticleId IdType="pubmed">32984764</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashraf S, Alsharedi M. COVID-19 induced immune thrombocytopenic purpura case report. Stem Cell Investig. 2021;8:14&#x2013;14. doi: 10.21037/sci-2020-060.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/sci-2020-060</ArticleId><ArticleId IdType="pmc">PMC8327190</ArticleId><ArticleId IdType="pubmed">34386543</ArticleId></ArticleIdList></Reference><Reference><Citation>Guirguis N, Rehman T, Shams Y, Gordon M, Mekhaiel E, Rozell S. SARS-CoV-2 Infection Inducing Immune Thrombocytopenic Purpura Case Series. Ochsner Journal. 2021;21(2):187&#x2013;189. doi: 10.31486/toj.20.0100.</Citation><ArticleIdList><ArticleId IdType="doi">10.31486/toj.20.0100</ArticleId><ArticleId IdType="pmc">PMC8238109</ArticleId><ArticleId IdType="pubmed">34239380</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohli RS, Bleibel W, Bleibel H. Concurrent immune thrombocytopenic purpura and Guillain-Barre syndrome in a patient with Hashimoto's thyroiditis. Am J Hematol. 2007;82(4):307&#x2013;308. doi: 10.1002/ajh.20771.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.20771</ArticleId><ArticleId IdType="pubmed">16986132</ArticleId></ArticleIdList></Reference><Reference><Citation>Mah&#xe9;vas M, Moulis G, Andres E, Riviere E, Garzaro M, Crickx E, et al. Clinical characteristics, management and outcome of COVID-19-associated immune thrombocytopenia: a French multicentre series. Br J Haematol. 2020 doi: 10.1111/bjh.17024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.17024</ArticleId><ArticleId IdType="pmc">PMC7404899</ArticleId><ArticleId IdType="pubmed">32678953</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoraka S, Ferreira MLB, Mohebbi SR, Ghaemi A. SARS-CoV-2 Infection and Guillain-Barr&#xe9; Syndrome A Review on Potential Pathogenic Mechanisms. Front Immunol. 2021;12:674922&#x2013;674922. doi: 10.3389/fimmu.2021.674922.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.674922</ArticleId><ArticleId IdType="pmc">PMC8141918</ArticleId><ArticleId IdType="pubmed">34040615</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation. Pathogens. 2021;10(6):763&#x2013;763. doi: 10.3390/pathogens10060763.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens10060763</ArticleId><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="pubmed">34204243</ArticleId></ArticleIdList></Reference><Reference><Citation>Houen G, Trier NH. Epstein-Barr Virus and Systemic Autoimmune Diseases. Front Immunol. 2020;11:587380&#x2013;587380. doi: 10.3389/fimmu.2020.587380.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.587380</ArticleId><ArticleId IdType="pmc">PMC7817975</ArticleId><ArticleId IdType="pubmed">33488588</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrillo-Larco RM, Ravaglia S, Vizcarra JA, Altez-Fernandez C. COVID-19 and Guillain-Barre Syndrome A systematic review of case reports. Wellcome Open Res. 2020;5:107&#x2013;107. doi: 10.12688/wellcomeopenres.15987.2.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/wellcomeopenres.15987.2</ArticleId><ArticleId IdType="pmc">PMC7509591</ArticleId><ArticleId IdType="pubmed">32995555</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz Gil W. Diagn&#xf3;stico y tratamiento de la p&#xfa;rpura trombocitop&#xe9;nica inmunol&#xf3;gica. Rev Med Hered. 2015;26(4):246&#x2013;255. doi: 10.20453/rmh.v26i4.2708.</Citation><ArticleIdList><ArticleId IdType="doi">10.20453/rmh.v26i4.2708</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Rumeileh S, Abdelhak A, Foschi M, Tumani H, Otto M. Guillain-Barr&#xe9; syndrome spectrum associated with COVID-19 an up-to-date systematic review of 73 cases. J Neurol. 2021;268(4):1133&#x2013;1170. doi: 10.1007/s00415-020-10124-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-10124-x</ArticleId><ArticleId IdType="pmc">PMC7445716</ArticleId><ArticleId IdType="pubmed">32840686</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>